The Hexosamine Biosynthetic Pathway as a Therapeutic Target after Cartilage Trauma: Modification of Chondrocyte Survival and Metabolism by Glucosamine Derivatives and PUGNAc in an Ex Vivo Model
The hexosamine biosynthetic pathway (HBP) is essential for the production of uridine diphosphate N-acetylglucosamine (UDP-GlcNAc), the building block of glycosaminoglycans, thus playing a crucial role in cartilage anabolism. Although O-GlcNAcylation represents a protective regulatory mechanism in ce...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-07-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/22/14/7247 |
id |
doaj-b0847e7a3bed4102b0a9be521cf46f2c |
---|---|
record_format |
Article |
spelling |
doaj-b0847e7a3bed4102b0a9be521cf46f2c2021-07-23T13:45:09ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672021-07-01227247724710.3390/ijms22147247The Hexosamine Biosynthetic Pathway as a Therapeutic Target after Cartilage Trauma: Modification of Chondrocyte Survival and Metabolism by Glucosamine Derivatives and PUGNAc in an Ex Vivo ModelJana Riegger0Julia Baumert1Frank Zaucke2Rolf E. Brenner3Division for Biochemistry of Joint and Connective Tissue Diseases, Department of Orthopedics, University of Ulm, 89081 Ulm, GermanyDivision for Biochemistry of Joint and Connective Tissue Diseases, Department of Orthopedics, University of Ulm, 89081 Ulm, GermanyDr. Rolf M. Schwiete Research Unit for Osteoarthritis, Department of Orthopaedics (Friedrichsheim), University Hospital Frankfurt, Goethe University, 60528 Frankfurt/Main, GermanyDivision for Biochemistry of Joint and Connective Tissue Diseases, Department of Orthopedics, University of Ulm, 89081 Ulm, GermanyThe hexosamine biosynthetic pathway (HBP) is essential for the production of uridine diphosphate N-acetylglucosamine (UDP-GlcNAc), the building block of glycosaminoglycans, thus playing a crucial role in cartilage anabolism. Although O-GlcNAcylation represents a protective regulatory mechanism in cellular processes, it has been associated with degenerative diseases, including osteoarthritis (OA). The present study focuses on HBP-related processes as potential therapeutic targets after cartilage trauma. Human cartilage explants were traumatized and treated with GlcNAc or glucosamine sulfate (GS); PUGNAc, an inhibitor of O-GlcNAcase; or azaserine (AZA), an inhibitor of GFAT-1. After 7 days, cell viability and gene expression analysis of anabolic and catabolic markers, as well as HBP-related enzymes, were performed. Moreover, expression of catabolic enzymes and type II collagen (COL2) biosynthesis were determined. Proteoglycan content was assessed after 14 days. Cartilage trauma led to a dysbalanced expression of different HBP-related enzymes, comparable to the situation in highly degenerated tissue. While GlcNAc and PUGNAc resulted in significant cell protection after trauma, only PUGNAc increased COL2 biosynthesis. Moreover, PUGNAc and both glucosamine derivatives had anti-catabolic effects. In contrast, AZA increased catabolic processes. Overall, “fueling” the HBP by means of glucosamine derivatives or inhibition of deglycosylation turned out as cells and chondroprotectives after cartilage trauma.https://www.mdpi.com/1422-0067/22/14/7247hexosamine biosynthetic pathwaycartilage traumapost-traumatic osteoarthritischondrocytesO-GlcNAcylationglucosamine |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Jana Riegger Julia Baumert Frank Zaucke Rolf E. Brenner |
spellingShingle |
Jana Riegger Julia Baumert Frank Zaucke Rolf E. Brenner The Hexosamine Biosynthetic Pathway as a Therapeutic Target after Cartilage Trauma: Modification of Chondrocyte Survival and Metabolism by Glucosamine Derivatives and PUGNAc in an Ex Vivo Model International Journal of Molecular Sciences hexosamine biosynthetic pathway cartilage trauma post-traumatic osteoarthritis chondrocytes O-GlcNAcylation glucosamine |
author_facet |
Jana Riegger Julia Baumert Frank Zaucke Rolf E. Brenner |
author_sort |
Jana Riegger |
title |
The Hexosamine Biosynthetic Pathway as a Therapeutic Target after Cartilage Trauma: Modification of Chondrocyte Survival and Metabolism by Glucosamine Derivatives and PUGNAc in an Ex Vivo Model |
title_short |
The Hexosamine Biosynthetic Pathway as a Therapeutic Target after Cartilage Trauma: Modification of Chondrocyte Survival and Metabolism by Glucosamine Derivatives and PUGNAc in an Ex Vivo Model |
title_full |
The Hexosamine Biosynthetic Pathway as a Therapeutic Target after Cartilage Trauma: Modification of Chondrocyte Survival and Metabolism by Glucosamine Derivatives and PUGNAc in an Ex Vivo Model |
title_fullStr |
The Hexosamine Biosynthetic Pathway as a Therapeutic Target after Cartilage Trauma: Modification of Chondrocyte Survival and Metabolism by Glucosamine Derivatives and PUGNAc in an Ex Vivo Model |
title_full_unstemmed |
The Hexosamine Biosynthetic Pathway as a Therapeutic Target after Cartilage Trauma: Modification of Chondrocyte Survival and Metabolism by Glucosamine Derivatives and PUGNAc in an Ex Vivo Model |
title_sort |
hexosamine biosynthetic pathway as a therapeutic target after cartilage trauma: modification of chondrocyte survival and metabolism by glucosamine derivatives and pugnac in an ex vivo model |
publisher |
MDPI AG |
series |
International Journal of Molecular Sciences |
issn |
1661-6596 1422-0067 |
publishDate |
2021-07-01 |
description |
The hexosamine biosynthetic pathway (HBP) is essential for the production of uridine diphosphate N-acetylglucosamine (UDP-GlcNAc), the building block of glycosaminoglycans, thus playing a crucial role in cartilage anabolism. Although O-GlcNAcylation represents a protective regulatory mechanism in cellular processes, it has been associated with degenerative diseases, including osteoarthritis (OA). The present study focuses on HBP-related processes as potential therapeutic targets after cartilage trauma. Human cartilage explants were traumatized and treated with GlcNAc or glucosamine sulfate (GS); PUGNAc, an inhibitor of O-GlcNAcase; or azaserine (AZA), an inhibitor of GFAT-1. After 7 days, cell viability and gene expression analysis of anabolic and catabolic markers, as well as HBP-related enzymes, were performed. Moreover, expression of catabolic enzymes and type II collagen (COL2) biosynthesis were determined. Proteoglycan content was assessed after 14 days. Cartilage trauma led to a dysbalanced expression of different HBP-related enzymes, comparable to the situation in highly degenerated tissue. While GlcNAc and PUGNAc resulted in significant cell protection after trauma, only PUGNAc increased COL2 biosynthesis. Moreover, PUGNAc and both glucosamine derivatives had anti-catabolic effects. In contrast, AZA increased catabolic processes. Overall, “fueling” the HBP by means of glucosamine derivatives or inhibition of deglycosylation turned out as cells and chondroprotectives after cartilage trauma. |
topic |
hexosamine biosynthetic pathway cartilage trauma post-traumatic osteoarthritis chondrocytes O-GlcNAcylation glucosamine |
url |
https://www.mdpi.com/1422-0067/22/14/7247 |
work_keys_str_mv |
AT janariegger thehexosaminebiosyntheticpathwayasatherapeutictargetaftercartilagetraumamodificationofchondrocytesurvivalandmetabolismbyglucosaminederivativesandpugnacinanexvivomodel AT juliabaumert thehexosaminebiosyntheticpathwayasatherapeutictargetaftercartilagetraumamodificationofchondrocytesurvivalandmetabolismbyglucosaminederivativesandpugnacinanexvivomodel AT frankzaucke thehexosaminebiosyntheticpathwayasatherapeutictargetaftercartilagetraumamodificationofchondrocytesurvivalandmetabolismbyglucosaminederivativesandpugnacinanexvivomodel AT rolfebrenner thehexosaminebiosyntheticpathwayasatherapeutictargetaftercartilagetraumamodificationofchondrocytesurvivalandmetabolismbyglucosaminederivativesandpugnacinanexvivomodel AT janariegger hexosaminebiosyntheticpathwayasatherapeutictargetaftercartilagetraumamodificationofchondrocytesurvivalandmetabolismbyglucosaminederivativesandpugnacinanexvivomodel AT juliabaumert hexosaminebiosyntheticpathwayasatherapeutictargetaftercartilagetraumamodificationofchondrocytesurvivalandmetabolismbyglucosaminederivativesandpugnacinanexvivomodel AT frankzaucke hexosaminebiosyntheticpathwayasatherapeutictargetaftercartilagetraumamodificationofchondrocytesurvivalandmetabolismbyglucosaminederivativesandpugnacinanexvivomodel AT rolfebrenner hexosaminebiosyntheticpathwayasatherapeutictargetaftercartilagetraumamodificationofchondrocytesurvivalandmetabolismbyglucosaminederivativesandpugnacinanexvivomodel |
_version_ |
1721287937115553792 |